Gland Pharma Names Shyamakant Giri as New CEO Starting January 2025

Gland Pharma, backed by China’s Fosun Pharma, announced on Friday that its Board of Directors has approved the appointment of Shyamakant Giri as the new chief executive officer (CEO) of the company. Giri is set to officially take on the role starting January 15, 2025, as stated in a company announcement to the stock exchanges.

Srinivas Sadu, the current CEO and executive chairman, will remain in his position as executive chairman and will continue to support the company during its next phase of growth.

Shyamakant Giri is currently the president of India business and emerging markets at Amneal Pharmaceuticals, a US-based company. In this role, he is responsible for expanding commercial operations and growth in India and other global markets.

Before joining Amneal, Giri served as the CEO of Rivaara Labs. He has a strong background in the pharmaceutical industry, having spent nearly 18 years with Abbott India, AbbVie (in the India region), and Abbott Diagnostics, where he held various positions.

According to Gland Pharma’s statement, Giri brings over 25 years of strategic and operational experience in pharmaceuticals, medical devices, diagnostics, and healthcare services. He has worked with leading Indian and multinational organizations across Asia, Africa, the Middle East, North Africa, and Latin America. Giri has a proven track record in creating new ventures, enhancing existing businesses, developing leaders, identifying value creation opportunities, and executing plans effectively.

Giri began his career with Wockhardt, where he worked from 1999 to 2002. He holds a master’s degree in marketing management from the Jamnalal Bajaj Institute of Management Studies and a master’s degree in science (organic chemistry) from Mumbai University. Additionally, he has completed an executive program at INSEAD in Singapore and a program in hospital management at the Indian Institute of Management, Ahmedabad.